Cutler Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Cutler Group’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10	Closed	–	–	3739
2023 Q4	$0	Buy	+10	New	+$411	﹤0.01%	4408
2021 Q4	–	Sell	-30	Closed	-$3K	–	6154
2021 Q3	$3K	Buy	+30	New	+$3.36K	﹤0.01%	4883

Other funds holding VRCA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Cutler Group's VRCA Position: Q1 2024 in Review

Cutler Group sold out of Verrica Pharmaceuticals (VRCA) in Q1 2024, closing a stake of 10 shares.

Cutler Group first reported a position in VRCA in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q3 2021. 60 funds tracked by Wall St. Rank hold VRCA as of Q1 2024.

Cutler Group reported no remaining Verrica Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 10 Verrica Pharmaceuticals shares in Q1 2024.
Cutler Group first reported a position in Verrica Pharmaceuticals in Q3 2021 and held it in 2 quarters.
Cutler Group's Verrica Pharmaceuticals position peaked at $3K in Q3 2021.
60 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.